Search Results

TherOx Completes Enrollment in Pilot Study of Next-Generation SSO2 Therapy as Adjunct to PCI for AMI

September 11, 2013—TherOx, Inc. (Irvine, CA) announced completion of enrollment in the multicenter pilot study of the company's second-generation system that delivers supersaturated oxygen (SSO2) therapy for reduction of infarct size after an acute myocardial infarction (AMI).

IDE Study Begins for TherOx's Next-Generation Supersaturated Oxygen Therapy to Treat AMI

February 6, 2013—TherOx, Inc. (Irvine, CA) announced the initiation of a multicenter investigational device exemption (IDE) pilot study of the company's second-generation system that delivers supersaturated oxygen (SSO2) therapy to reduce infarct size after an acute myocardial infarction.